Navigation Links
The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Date:3/13/2008

Future Generation Treatment from Abbott Shows No Thrombosis, Low MACE Rates

Out to One Year in Preliminary Clinical Study of Thirty Patients

ABBOTT PARK, Ill., March 13 /PRNewswire-FirstCall/ -- Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (retreatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007 (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0529.htm ). Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the o
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
2. The Lancet Publishes Vasogens ACCLAIM Results
3. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
4. Consortium publishes Phase II map of human genetic variation
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. NPS Pharmaceuticals Reports 2007 Financial Results
10. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
(Date:12/15/2014)... NEW YORK & PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI ), a leading ... announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. ... Israel,s Office of the Chief ... has been in receipt of grant support from the ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... isn,t a very powerful force, but it matters for small ... Nanowires are so tiny that a human hair would ... meter. Because of their small size, surface tension that occurs ... This is a problem because the wires are seen as ...
... July 21 The Lucian Leape Institute at ... discussion and special evening program at its Third Annual ... .  David Blumenthal, M.D., M.P.P., will deliver a keynote address ... as a patient safety lever and the focus placed on ...
... N.C. , July 21 Chimerix, Inc., a biotechnology ... its clinical management team with the appointment of Timothy King ... MD, as Vice President of Clinical Research.   , ... In these new roles, Mr. ...
Cached Biology Technology:Engineering researchers simplify process to make world's tiniest wires 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 2David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 3David Blumenthal, HHS National Coordinator for Health Information Technology, to Speak at Lucian Leape Institute Third Annual Forum & Gala on Sept. 16 4Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... University have received a $486,000 Doris Duke Foundation award ... patients will suffer an acute crisis and monitor the ... that during acute crisis, patients, red blood cells change ... sticky and block flow of healthy oxygen-carrying cells in ...
... a fast-food restaurant reduces the calories in a children,s ... size of French fries? Would children compensate by choosing ... Cornell University, Dr. Brian Wansink and Dr. Andrew Hanks, ... answer that question. Prior to 2012, the Happy ...
... USA - Can spaceborne radar help predict sinkholes? What ... affect sub-seafloor environments? Can OAE2 help us understand current ... When did vast landmasses first emerge above sea level? ... reveal about central Taiwan? How do you reconstruct snapshots ...
Cached Biology News:Learning to predict sickle cell crisis and monitor treatment 2Learning to predict sickle cell crisis and monitor treatment 3Learning to predict sickle cell crisis and monitor treatment 4Healthier Happy Meals 2New geology research explores intriguing questions 2New geology research explores intriguing questions 3New geology research explores intriguing questions 4New geology research explores intriguing questions 5New geology research explores intriguing questions 6New geology research explores intriguing questions 7New geology research explores intriguing questions 8New geology research explores intriguing questions 9
... the consumable measurement plate for ... individually controlled measurement sites. Each ... liquid flow channel system that ... solution and compound applications necessary ...
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... Caliper's iLink makes it easy to supply ... instruments. Developed with operator convenience in mind, ... shoot' ease of use. The iLink software ... for assays or sub-assays, that can be ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
Biology Products: